5809 studies found for:    vaccine
Show Display Options
Rank Status Study
21 Completed Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Condition: Meningococcal Infections
Interventions: Biological: rMenB and concomitantly routine infant vaccinations;   Biological: rMenB and routine infant vaccinations;   Biological: rMenB and concomitantly routine infant vaccinations;   Biological: Routine infant vaccines
22 Completed
Has Results
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Conditions: Influenza Vaccines;   Influenza Virus
Interventions: Biological: GSK Biologicals' influenza vaccine GSK1557482A;   Biological: Vaxigrip
23 Completed
Has Results
Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
Condition: Influenza
Interventions: Biological: Inactivated H1N1 Vaccine;   Biological: AS03
24 Completed School Located Adolescent Vaccination Study
Condition: School Located Vaccine Program
Intervention: Behavioral: School Located Vaccine (SLV) Program
25 Completed
Has Results
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-Hib-IPV;   Biological: PCV;   Biological: MMR;   Biological: Hib
26 Unknown  Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Conditions: Pneumococcal Vaccines;   HIV;   HIV Infections
Intervention: Biological: Prevenar and Pneumo23
27 Completed
Has Results
Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal vaccine GSK1024850A;   Biological: Tritanrix-HepB/Hib;   Biological: measles;   Biological: Rotarix;   Biological: Local OPV
28 Active, not recruiting Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: AIDSVAX B/E;   Biological: Placebo for ALVAC-HIV;   Biological: Placebo for AIDSVAX B/E;   Biological: Hepatitis B vaccine;   Biological: Tetanus toxoid vaccine;   Biological: Placebo for hepatitis B vaccine;   Biological: Placebo for tetanus vaccine
29 Completed
Has Results
Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)
Condition: Vaccine Response Impaired
Interventions: Biological: Tetanus & Diphtheria booster vaccine (Td);   Biological: TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine];   Biological: Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)
30 Recruiting Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection
Condition: Vaccine Overdose of Undetermined Intent
Interventions: Biological: prophylactic peptide vaccine;   Biological: therapeutic peptide vaccine
31 Completed Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years
Condition: Influenza
Interventions: Biological: Seasonal Influenza DNA vaccine;   Biological: TIV
32 Completed
Has Results
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
Condition: Influenza
Interventions: Biological: Cell culture-derived influenza vaccine;   Biological: Egg-derived influenza virus vaccine;   Biological: Placebo
33 Recruiting Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: CYD Dengue and Japanese Encephalitis Vaccines;   Biological: Japanese Encephalitis and CYD Dengue Vaccines
34 Completed
Has Results
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-IPV/Hib;   Biological: HBV;   Biological: PCV;   Biological: MMR
35 Completed
Has Results
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
Condition: Influenza
Interventions: Biological: Cell culture-derived trivalent subunit influenza vaccine (cTIV);   Biological: Egg-derived trivalent subunit influenza vaccine (TIV)
36 Active, not recruiting Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Conditions: Childhood Cancer;   Multiple Diseases
Interventions: Biological: Immunization Schedule patients <7 years.;   Biological: Immunization Schedule patients > or = to 7 years and <11 years of age;   Biological: Immunization Schedule patients > or = to 11 years of age
37 Completed
Has Results
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
Conditions: Medication Adherence;   Substance Abuse, Intravenous;   Risk Behavior;   Hepatitis A;   Hepatitis B;   Hepatitis C
Interventions: Biological: Hepatitis A & B vaccine;   Behavioral: Outreach;   Behavioral: AIC;   Behavioral: SEP
38 Completed
Has Results
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
39 Completed
Has Results
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
Condition: Influenza
Interventions: Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV);   Biological: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)
40 Completed
Has Results
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years